VCANBIO's subsidiary VUM02 injection has been approved for clinical trials
I'm PortAI, I can summarize articles.
VCANBIO's wholly-owned subsidiary Wuhan Optics Valley VCANBIO Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration on September 9, 2025, to conduct clinical trials for VUM02 injection. This injection is a cryopreserved cell preparation independently developed by the company, primarily used for the treatment of severe/critical pneumonia
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments